clinical trial · NCT07147569
TAMBE Japan Post-Marketing Surveillance
W.L.Gore & Associates·—·recruiting·n = 100
Thoracoabdominal Aortic AneurysmPararenal Aortic AneurysmGORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis
brief summary
To evaluate the safety and efficacy of multi component system (TAMBE device) including GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (Aortic Component; AC) under post-marketing use.
started
Mar 1, 2026
primary completion
Feb 28, 2034
completion
Feb 28, 2034
last updated
Feb 18, 2026
official title
GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis Post-Marketing Surveillance
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol